Boothbay Fund Management’s CureVac CVAC Stock Holding History

Boothbay Fund Management’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-113,200	Closed	-$333K	–	1578
2024 Q3	$333K	Buy	+113,200	New	+$373K	0.01%	1172

Other funds holding CVAC

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return

Boothbay Fund Management's CVAC Position: Q4 2024 in Review

Boothbay Fund Management sold out of CureVac (CVAC) in Q4 2024, closing a stake of 113,200 shares — an estimated $333K sold.

Boothbay Fund Management first reported a position in CVAC in Q3 2024 and held it in 1 quarter. The position peaked at $333K in Q3 2024. 75 funds tracked by Wall St. Rank hold CVAC as of Q4 2024.

Boothbay Fund Management reported no remaining CureVac position as of Q4 2024 after selling out during the quarter.
Boothbay Fund Management sold 113,200 CureVac shares in Q4 2024, an estimated $333K.
Boothbay Fund Management first reported a position in CureVac in Q3 2024 and held it in 1 quarter.
Boothbay Fund Management's CureVac position peaked at $333K in Q3 2024.
75 funds tracked by Wall St. Rank held CureVac as of Q4 2024.

Based on Boothbay Fund Management's 13F filing for Q4 2024, filed 14 Feb 2025.